Lilly, a pharmaceutical speed-reading agency, terminated the ACTIV-3 study of AZ's new crown vaccine to restart successful immunization

October 27, 2020 / Medical Information At a Glance: Novartis' potential "first-in-class" oral therapy has positive interim clinical results; AstraZenece's new crown vaccine AZD1222 produces an immune response in older groups; NEJM publishes Important Phase 3 clinical results from Bayer; Sonic Pharmaceuticals is officially listed on the Hong Kong Stock Exchange... Daily fresh medicine news, speed reading society and you pay attention to! Part 1 Policy Brief Shaanxi Province five days after the third batch of state mining landed on October 26, Shaanxi Provincial Health Insurance Bureau issued "on the third batch of state-organized drugs centralized procurement and use of drug price adjustment work notice."
, from November 25, 2020, Shaanxi Province to implement the third batch of national collection results.
(Shaanxi Provincial Health Insurance Bureau) Qinghai Province 54 types of medical supplies down to the lowest price qinghai Province drugs and medical supplies centralized procurement network recently released the Qinghai Provincial Public Medical Institutions Procurement Alliance Orthopaedic Joints high-value medical supplies procurement documents, involving 29 categories of 54 varieties of orthopaedic supplies.
document shows that the declared enterprises are required to provide the lowest price of the first ticket of the sales invoice for medical institutions in Qinghai Province from 2019 to date, and the quotation of the declared enterprises shall not be higher than the minimum supply price of the existing medical institutions in China.
(Qinghai Province, pharmaceutical and medical supplies centralized procurement network) Part 2 after observation of the first sound pharmaceutical industry officially listed on the Hong Kong Stock Exchange today, the first sound pharmaceutical industry officially landed on the Hong Kong Stock Exchange.
the company's share issue price was HK$13.70 per share, and the net proceeds received were estimated at about HK$3,392.4 million, according to the company's announcement.
(Sina Pharmaceutical News) Keystone Pharmaceuticals authorized EQRx to develop Shugli monoanti and CS1003 Today, Keystone Pharmaceuticals announced a global strategic partnership with EQRx, which will exclusively authorize EQRx in Greater China The development and commercialization of Shugli monoanti and CS1003, two late-stage oncology immunotherapy drugs, will help EQRx gain a global market competitive advantage over existing therapies in terms of target adaptation.
(Pharmaceutical Rubik's Cube) Idea Di Pharmaceuticals obtained the exclusive rights of hai and drug two new analgesic drugs in China Today, Thoughti Pharmaceuticals and Haihe Pharmaceuticals announced that the two sides on Hai and pharmaceutical two analgesic innovative drugs RMX1001 and RMX1002 reached a cooperation, Thoughti Pharmaceuticals will get the two new drugs in China research and development, production and commercial exclusive rights.
both drugs have the potential to replace traditional nonsteroidal anti-inflammatory drugs and become new analgesics, and have completed Phase 1 clinical studies in China.
's $4 billion acquisition of AskBio's widening cell and gene therapy product pipeline on October 26th, Bayer announced the acquisition of Asklepios BioPharmaceutical, under which Bayer will make an upfront payment of $2 billion and a milestone payment of up to $2 billion.
(Immediate Drug News) qualitative peptide biology completed round A financing recently, qualitative peptide organisms completed round A financing, used to promote the company's two class of innovative drugs and two biosypole products clinical declaration and follow-up pipeline reserve project progress.
(E Drug Manager) Part 3 Pharmaceutical Information Novart's potential "first-in-class" oral therapy mid-clinical results Positive Novart announced today that its target complement signaling pathway of the potential "first-in-class" oral therapy iptacopan (LNP023) has obtained positive mid-stage clinical results in Phase 2 clinical trials for patients with C3 renal ococyttes.
significantly reduced proteinuria levels in patients with C3G.
(Drug Mingkangde) Sanofi/Regenerative Dupixent showed significant signs of improving eosinophilic esophpathy for the first time on October 26, regeneratives and Sanofi announced more positive results for the critical Phase 3 clinical trial Part A evaluating Dupilumab for treatment of patients aged 12 years and older with acidophilitis®.
the latest data show a further improvement in the severity and progress of the disease at the microscopic level, as well as normalization of gene expression patterns associated with type 2 inflammation.
(Sina Pharmaceutical News) Lilly terminates the new coronal and antibody ACTIV-3 study October 26, Lilly issued a statement to terminate the ACTIV-3 clinical study, the latest data of the study show that its new coronal and antibody LY-CoV555 (bamlanivimab) is unlikely to improve the late recovery of hospitalized COVID-19 patients.
(Pharmaceutical Rubik's Cube) AstraZenecom's new crown vaccine AZD1222 has produced an immune response in older populations just days after the FDA restarted AstraZeneta III COVID-19 vaccine trials, the company said its new coronavirus vaccine AZD1222 has successfully produced an immune response in the elderly and young populations.
(Sina Pharmaceutical News) NEJM published Bayer's important Phase 3 clinical results Bayer in the research therapy finerenone important clinical trial FIDELIO-DKD results recently announced.
study showed that finerenone had significant kidney and cardiovascular benefits for people with type 2 diabetes who combined chronic kidney disease, and that finerenone slowed the progression of kidney disease by 18 percent over a medium 2.6-year period compared to current standard treatments.
results were published simultaneously in NEJM.
(Medical New Perspectives) IBM, Pfizer and AI U.S. drug giant Pfizer Inc. and IT giant IBM Co. recently jointly published an article in The Lancet Intelligence Media, bringing an intelligent choice for the early detection of Alzheimer's disease.
AI model, created by the two companies, can help predict the eventual onset of Alzheimer's disease with 71% accuracy based on language samples.
(Biological Discovery) gene therapy PBGM01 was recognized by EMA Orphan Pharmaceuticals on October 26, Pasage Bio, inc., which specializes in the development of conversion therapies for rare single-gene central nervous system diseases, announced that the European Commission has awarded the company the title of PBGM01 Orphan Drug, a pilot gene therapy candidate for the treatment of GM1 neuro-glycoside lipid storing disorder.
(Sina Pharmaceutical News) IDH1 inhibitor registration test topline results positive Forma company announced today that it has obtained positive top line data in a mid-term analysis of a registered Phase 2 clinical trial in the study of IDH1 selective inhibitor olutasidenib.
patients with R/R AML with IDH1 mutation were well-to-do with The Single Drug Treatment of Olutasidenib, with a compound complete remission rate of 33.3% for the main therapeutic endpoint, of which CR was 30%.
(Pharmaceutical Mingkangde) AXA Pharma MDM2-p53 inhibitor APG-115 approved by China's IB/II phase clinical trial AXA Pharma today announced that the company's new class 1 drug MDM2-p53 inhibitor APG-115 has obtained CDE clinical license, will carry out joint PD-1/PD-L1 inhibitor treatment of advanced liposarcoma or other advanced solid tumor patients IB/II clinical study.
(AGENCY) Kangfang BioCD73 monoantitor in New Zealand completed the first health subject administration today, Kangfang Bio announced its own research and development of innovative drug CD73 monoclonal antibody AK119 in a clinical trial in New Zealand completed the first health subject administration, AK119 is intended to be used to treat patients with the new coronavirus.
(Pharmaceutical Rubik's Cube) Kangfang BioPharma's single-line anti-three-line treatment of nasopharyngeal cancer was approved by the FDA fast-track eligibility today, Kangfang Bio and China Biopharmaceutical Co., Ltd. jointly announced that Pian puli (AK105) for third-line treatment of metastatic nasopharyngeal cancer has been granted fast-track approval channel eligibility by the Fda.
fda's award of fast-track eligibility significantly supports and accelerates The Amplify's business expansion program in the United States.
(Pharmaceutical Rubik's Cube) Boya because of the submission of the country's first CRISPR gene editing therapy clinical trial application today, Boya because announced that CDE has accepted its blood transfusion-dependent β thalassemia gene editing therapy product ET-01, that is, CRISPR/ Cas9 gene modification BCL11A red line enhancer auto-CD34 plus hematocytosis dry ancestral cell injection application.
(Pharmaceutical Rubik's Cube) four-ring pharmaceutical exclusive agent botulinum toxin Letti, approved by the NMPA on October 26, four-ring pharmaceutical announced that by the company's sole agent, The Korean biopharmaceutical company Hugel produced "injected type A botulinum toxin ( Letybo 100U, commodity name: Lotte) "was officially approved for listing by the State Drug Administration on October 21, 2020, becoming the fourth type A botulinum toxin to be approved for listing in China and the first of its kind in Korea.
(Sina Pharmaceutical News) Colum will take 1.9 billion anaesthetic on October 26, Colum Pharmaceuticals propofol medium/long chain fat emulsion into the administrative approval stage, the product belongs to the neurological drug anesthetic.
currently, the nervous system area of Colum Pharmaceuticals has two new classification products in review, neither of which has been approved.
(Minenet) Tecentriq and Beval pearl single-line treatment of liver cancer will be approved in China on October 26, Roche in China submitted the second adaptation application of Tecentriq entered the "in-approval" stage, is expected to be formally approved in the near future, for the combined beval pearl single anti-treatment has not previously received systemic treatment of non-excisive hepatocellular cancer patients.
(Medical Rubik's Cube)